Tag: Phase
-
HL Klemove and Lenovo Forge Partnership to Lead the Autonomous Driving Market
Joint development of high-performance AI computing (HPC) solutions to pursue global OEM opportunities and expand mass-production programsSEOUL, South Korea, Sept. 17, 2026 /PRNewswire/ — HL Klemove, HL Group’s autonomous driving solutions specialist, has entered into a strategic partnership with gl…
-
Miral Invests AED 12 billion to Shape the Next Phase of Yas Island's Growth
A robust five-year pipeline of new developments and enhancements will expand world-class attractions, grow hotel capacity, and further strengthen Yas Island’s global appealABU DHABI, UAE, Sept. 14, 2026 /PRNewswire/ — Miral, Abu Dhabi’s leading creator of immersive destinations and experiences, wil…
-
Treeni Sustainability Solutions Appoints Vivek Rawat to Its Advisory Board to Accelerate Next Phase of Growth
Go-to-market and revenue leader to advise Treeni on building a Scalable and Sustainable growth engine as it expands its consulting-led, outcome-accountable ESG managed services.BENGALURU, India, Sept. 11, 2026 /PRNewswire/ — Treeni Sustainability Solutions, a consulting-led ESG managed services com…
-
Aarti Industries Commissions Phase I of Zone IV, Unlocking New High-Value Manufacturing Opportunities
Phase I brings Calcium Chloride, PEDA and a part of Multipurpose Plant on stream, strengthening downstream integration, application diversification and flexible manufacturing capabilitiesMUMBAI, India, Sept. 7, 2026 /PRNewswire/ — Aarti Industries Limited (AIL), a leading global speciality chemical…
-
NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury
Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life – Spinal Cord Research Foundation.SCHLIEREN, Switzerland, Sept. 2, 2026 /PRNewswire/ — NovaGo Therapeutics AG, a clini…
-
Laminar Pharma Announces "Last Patient, Last Visit" in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients
PALMA DE MALLORCA, Spain, July 24, 2026 /PRNewswire/ — Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, today announced that the last patient has completed their last visit (LPLV) in the company’s Phase 2b/3 clinical trial of its …
Latest News
About the Author
Your reliable go-to for precise and up-to-date information!
We are dedicated to accuracy, impartiality, and providing news as it unfolds, earning the trust of a wide audience. Keep up with real-time updates on the latest events and trends.